| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Guidelines on the management of valvular heart disease (version 2012).
|
Eur Heart J
|
2012
|
10.70
|
|
2
|
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
|
Eur Heart J
|
2013
|
9.54
|
|
3
|
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
|
Eur J Cardiothorac Surg
|
2012
|
5.49
|
|
4
|
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2015
|
5.15
|
|
5
|
Lipoprotein(a) as a cardiovascular risk factor: current status.
|
Eur Heart J
|
2010
|
4.31
|
|
6
|
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
|
Eur Heart J
|
2011
|
3.00
|
|
7
|
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
|
J Am Coll Cardiol
|
2012
|
2.41
|
|
8
|
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function.
|
Eur Heart J
|
2005
|
2.33
|
|
9
|
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
|
Thromb Haemost
|
2014
|
2.29
|
|
10
|
The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?
|
Circulation
|
2003
|
2.03
|
|
11
|
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.
|
Am J Cardiol
|
2013
|
2.00
|
|
12
|
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).
|
Eur J Anaesthesiol
|
2010
|
1.92
|
|
13
|
[Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)].
|
G Ital Cardiol (Rome)
|
2013
|
1.53
|
|
14
|
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation].
|
G Ital Cardiol (Rome)
|
2009
|
1.52
|
|
15
|
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment.
|
Am Heart J
|
2005
|
1.52
|
|
16
|
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation.
|
Rev Esp Cardiol (Engl Ed)
|
2015
|
1.49
|
|
17
|
Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass.
|
J Thorac Cardiovasc Surg
|
2002
|
1.46
|
|
18
|
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients.
|
Thromb Haemost
|
2015
|
1.40
|
|
19
|
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2013
|
1.36
|
|
20
|
Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.
|
Thromb Haemost
|
2011
|
1.35
|
|
21
|
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.
|
Eur Heart J
|
2011
|
1.34
|
|
22
|
Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis.
|
Eur Heart J
|
2005
|
1.34
|
|
23
|
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.
|
BMJ
|
2013
|
1.32
|
|
24
|
Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis.
|
Ann Intern Med
|
2013
|
1.24
|
|
25
|
Antiplatelet agents for the treatment and prevention of atherothrombosis.
|
Eur Heart J
|
2011
|
1.23
|
|
26
|
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
|
Europace
|
2011
|
1.22
|
|
27
|
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
|
Thromb Haemost
|
2009
|
1.21
|
|
28
|
Insulin-like growth factor-1 as a vascular protective factor.
|
Circulation
|
2004
|
1.21
|
|
29
|
Hypercoagulable states in cardiovascular disease.
|
Circulation
|
2008
|
1.09
|
|
30
|
Erythropoietin in heart and vessels: focus on transcription and signalling pathways.
|
J Thromb Thrombolysis
|
2008
|
1.07
|
|
31
|
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
|
Eur Heart J
|
2010
|
1.05
|
|
32
|
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2013
|
0.99
|
|
33
|
Bedside monitoring of antiplatelet therapy for coronary stenting.
|
N Engl J Med
|
2013
|
0.95
|
|
34
|
Preoperative C-reactive protein level and outcome following coronary surgery.
|
Eur J Cardiothorac Surg
|
2002
|
0.91
|
|
35
|
Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials.
|
Clin Res Cardiol
|
2012
|
0.90
|
|
36
|
Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease.
|
Eur Heart J
|
2005
|
0.88
|
|
37
|
Leading avoidable cause of premature deaths worldwide: case for obesity.
|
Am J Med
|
2013
|
0.88
|
|
38
|
Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina.
|
Circulation
|
2003
|
0.86
|
|
39
|
Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
|
Eur J Heart Fail
|
2012
|
0.85
|
|
40
|
Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe?
|
Eur Heart J
|
2005
|
0.85
|
|
41
|
Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
|
Am J Cardiol
|
2007
|
0.85
|
|
42
|
Diurnal variation in platelet inhibition by clopidogrel.
|
Platelets
|
2011
|
0.84
|
|
43
|
Body fat and cardiovascular risk: understanding the obesity paradox.
|
Eur Heart J
|
2009
|
0.84
|
|
44
|
Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery.
|
J Thorac Cardiovasc Surg
|
2003
|
0.84
|
|
45
|
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
|
Thromb Haemost
|
2012
|
0.84
|
|
46
|
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2016
|
0.83
|
|
47
|
Reduced CD34+, renal anemia, and adverse outcomes.
|
Am Heart J
|
2006
|
0.82
|
|
48
|
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].
|
Kardiol Pol
|
2015
|
0.82
|
|
49
|
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials.
|
EuroIntervention
|
2011
|
0.82
|
|
50
|
Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries.
|
Am J Cardiol
|
2002
|
0.82
|
|
51
|
Predictors of exercise-induced platelet reactivity in patients with chronic stable angina.
|
J Cardiovasc Med (Hagerstown)
|
2009
|
0.81
|
|
52
|
Pregnancy-associated plasma protein-A and acute coronary syndromes: cause or consequence?
|
J Am Coll Cardiol
|
2005
|
0.81
|
|
53
|
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
|
J Thromb Thrombolysis
|
2003
|
0.81
|
|
54
|
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology.
|
Cardiol J
|
2011
|
0.80
|
|
55
|
Lost and found: an unusual late complication of the Angio-Seal closure device.
|
Int J Cardiol
|
2007
|
0.80
|
|
56
|
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction.
|
Eur J Clin Invest
|
2011
|
0.80
|
|
57
|
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials.
|
Atherosclerosis
|
2011
|
0.80
|
|
58
|
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety.
|
Circulation
|
2013
|
0.80
|
|
59
|
Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction.
|
Int J Cardiol
|
2009
|
0.79
|
|
60
|
Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease.
|
Heart
|
2007
|
0.78
|
|
61
|
Letter by Andreotti et al regarding article, "Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study".
|
Circulation
|
2007
|
0.78
|
|
62
|
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
|
J Cardiovasc Med (Hagerstown)
|
2009
|
0.78
|
|
63
|
Role of PAPP-A in atherothrombosis: messages to take home.
|
Atherosclerosis
|
2008
|
0.77
|
|
64
|
Pregnancy-associated plasma protein a as predictor of outcome in patients with suspected acute coronary syndromes.
|
Circulation
|
2004
|
0.77
|
|
65
|
Heart-kidney interactions in ischemic syndromes.
|
Circulation
|
2004
|
0.77
|
|
66
|
Interplay of platelet polymorphisms, risk factors, and von [corrected] Willebrand factor [corrected] in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease.
|
Blood Coagul Fibrinolysis
|
2005
|
0.77
|
|
67
|
Testosterone, tissue factor inhibition and vascular aging.
|
Thromb Haemost
|
2009
|
0.77
|
|
68
|
Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes.
|
Cytokine
|
2004
|
0.77
|
|
69
|
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)].
|
G Ital Cardiol (Rome)
|
2016
|
0.76
|
|
70
|
Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease.
|
Circulation
|
2003
|
0.76
|
|
71
|
Increased platelet reactivity due to platelet receptor polymorphisms? Not in the real world.
|
Arterioscler Thromb Vasc Biol
|
2003
|
0.75
|
|
72
|
Favorable cardiac risk among elderly breast carcinoma survivors.
|
Cancer
|
2004
|
0.75
|
|
73
|
[Reduced (bioavailability of) nitric oxide as a cause of adverse prognosis in anaemic patients].
|
G Ital Cardiol (Rome)
|
2011
|
0.75
|
|
74
|
Polycythemia, vascular function, and hemoglobin-nitric oxide reactions.
|
J Appl Physiol (1985)
|
2011
|
0.75
|
|
75
|
IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease.
|
Heart
|
2007
|
0.75
|
|
76
|
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome.
|
Haematologica
|
2004
|
0.75
|
|
77
|
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor.
|
Thromb Haemost
|
2008
|
0.75
|
|
78
|
Substandard life-saving drugs: a global concern.
|
Eur Heart J
|
2005
|
0.75
|
|
79
|
The unstable plaque: a broken balance.
|
Eur Heart J
|
2009
|
0.75
|
|
80
|
Hemoglobin levels, nitric oxide bioavailability and cardiovascular outcomes.
|
Am J Cardiol
|
2011
|
0.75
|
|
81
|
Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus.
|
J Cardiovasc Med (Hagerstown)
|
2008
|
0.75
|
|
82
|
Scintigraphic results in asymptomatic myocardial infarction patients with exercise-induced ST segment elevation.
|
Ital Heart J
|
2002
|
0.75
|
|
83
|
[Double antiaggregant therapy in patients with acute coronary syndrome undergoing coronary angioplasty revascularization. Pending clinical problems and effects of therapy non-compliance].
|
G Ital Cardiol (Rome)
|
2011
|
0.75
|
|
84
|
Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis.
|
J Thromb Thrombolysis
|
2008
|
0.75
|
|
85
|
Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein.
|
J Thromb Thrombolysis
|
2002
|
0.75
|
|
86
|
Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome.
|
Int J Antimicrob Agents
|
2004
|
0.75
|
|
87
|
IGF-1 and macrovascular complications of diabetes: alternative interpretations of recently published data.
|
Diabetes Care
|
2003
|
0.75
|
|
88
|
Preoteomics, metabolomics and progenitor cells in acute coronary syndromes.
|
J Thromb Thrombolysis
|
2006
|
0.75
|
|
89
|
EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis.
|
Expert Rev Hematol
|
2012
|
0.75
|
|
90
|
[Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation].
|
Ital Heart J Suppl
|
2002
|
0.75
|
|
91
|
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
|
G Ital Cardiol (Rome)
|
2014
|
0.75
|
|
92
|
Asymmetric dimethylarginine and impaired cardiovascular healing.
|
J Thromb Thrombolysis
|
2007
|
0.75
|
|
93
|
[Guidelines on the management of stable angina pectoris: executive summary].
|
G Ital Cardiol (Rome)
|
2006
|
0.75
|